1. Pegaharolines A - I, structurally novel indole alkaloids with anti-HSV-2 virus activities from Peganum harmala L. seeds.
- Author
-
Wu ZN, Zhang YB, Wang GC, Tang Q, Li YL, and Cheng W
- Subjects
- Molecular Structure, Chlorocebus aethiops, Vero Cells, Phytochemicals pharmacology, Phytochemicals isolation & purification, Animals, China, Antiviral Agents pharmacology, Antiviral Agents isolation & purification, Antiviral Agents chemistry, Seeds chemistry, Peganum chemistry, Herpesvirus 2, Human drug effects, Indole Alkaloids pharmacology, Indole Alkaloids isolation & purification, Indole Alkaloids chemistry
- Abstract
Leading by the antiviral activities against HSV-2 virus, bioactivity-guided the fraction of crude alkaloids from seeds of Peganum harmala led to the isolation of nine structurally novel indole alkaloids, pegaharolines A - I (1-9), and 11 known ones (10-20). Compound 3 was an unusual 6/5/5/5 spirotetracyclic indole-derived alkaloids featuring a classic bicyclic indole unit fused with an additional pyrrolizine ring via a spiral atom (C-3). Compound 4 was determined as a novel indole alkaloid, characterized with a rare hexacyclic 6/5/6/5-6/6 ring system, by a single-crystal X-ray diffraction. Compounds 5 and 6 were peculiar indole dimers featuring with the rare carbon skeleton of an octacyclic scaffold. Compounds 1-6 were six racemates. Most compounds exhibited different levels of antiviral activities against HSV-2. Especially, the anti-HSV-2 activity of compound 1 (IC
50 = 0.90 ± 0.10 μM) was much better than that of the positive control (acyclovir, IC50 = 1.12 ± 0.15 μM). In this study, the discovery of anti-HSV-2 components from the seeds of P. harmala, could benefit development and utilization of this plant in antiviral medicinal products., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF